Home›Trial›NCT06602479
🔬NCT06602479Phase 2RECRUITING

A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine

Study Summary

The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.

Conditions
Migraine
Interventions / Drugs
MEDI0618Placebo
View on ClinicalTrials.gov ↗
Sponsor
ABBV
AbbVie Inc
Immunology
C64/100
Study Details
Enrollment488 participants
Primary Completion—
Lead SponsorAbbVie
Data Retrieved2026-04-11 02:51:51.325867+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.